US Patent

US8084047 — Compositions and methods for treatment of eye disorders

Composition of Matter · Assigned to Sarcode Bioscience Inc · Expires 2026-05-17 · 0y expired

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds and methods for treating LFA-1 mediated diseases, including dry eye disorders, using LFA-1 antagonists.

USPTO Abstract

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Drugs covered by this patent

Patent Metadata

Patent number
US8084047
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-05-17
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Sarcode Bioscience Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.